Biogen (BIIB) Q1 2025: New Launches Drive 22% Sequential Growth as MS Headwinds Deepen

May 1, 2025 | By EarningsIQ Research

Biogen’s Q1 revealed a decisive shift as launch products now comprise nearly half of product revenue, offsetting accelerating MS declines. With rare disease and Alzheimer’s portfolios gaining traction, the company’s pipeline momentum and global diversification are reshaping its risk profile. Management’s focus on operational discipline and pipeline expansion sets the stage for a new era, though legacy erosion and market access hurdles remain.

Summary

• Portfolio Transformation: New launches now represent 45% of product revenue, signaling a critical inflection point.
• Pipeline Maturation: Five Phase III starts and multiple late-stage readouts underscore a diversified R&D strategy.
• MS Franchise Decline: Accelerating generic and biosimilar pressure in MS will continue to weigh on top-line results.

Performance Analysis

Biogen’s Q1 revenue grew 6% year over year to $2.4 billion, with launch products delivering approximately $200 million—up 22% sequentially and more than double year-ago levels. This growth is increasingly offsetting the legacy multiple sclerosis (MS) franchise, which declined 11% year over year due to biosimilar and generic competition, particularly for Tysabri and Tecfidera. The company’s rare disease and Alzheimer’s assets, including Lekembe, Skyclarus, and Zerzuve, are gaining commercial momentum, with Skyclarus up 59% year over year and Lekembe achieving nearly $100 million in quarterly sales. Spinraza, spinal muscular atrophy therapy, remained steady, seeing 4% U.S. growth and benefiting from one-time ex-U.S. items.

Profitability was pressured by upfront R&D charges and lower-margin contract manufacturing, with non-GAAP EPS down 18% to $3.02, largely due to a $165 million payment for the Stoke deal. Excluding this, EPS would have risen 8%. Free cash flow remained positive at $222 million even after absorbing the Stoke payment, and the balance sheet ended with $2.6 billion in cash. Management maintained its full-year revenue outlook, with growth in launch products expected to be outweighed by steeper MS declines.

• Launch Product Momentum: Four launch products now comprise 45% of product revenue, with sequential and year-over-year acceleration.
• MS Franchise Weakness: Ongoing biosimilar and generic entry, especially in Europe, will drive further declines in legacy MS revenue.
• Operating Leverage: Cost discipline and Fit for Growth savings are cushioning R&D expansion and launch investment.

Overall, Biogen’s financials reflect a business in the midst of a portfolio transition, with new launches and pipeline assets steadily gaining ground as MS headwinds intensify.

Executive Commentary

Strategic Positioning

1. Portfolio Diversification and Rare Disease Expansion

Biogen’s commercial mix is rapidly shifting away from MS toward rare disease and Alzheimer’s assets. The company’s four recent launches—Lekembe (Alzheimer’s), Skyclarus (rare neurology), Zerzuve (postpartum depression), and CalSati—now comprise 45% of product revenue. These products are in early stages of their global rollouts, with Lekembe recently approved in Europe and Skyclarus expanding to 26 markets. This shift reduces reliance on the declining MS franchise and lengthens the company’s growth runway.

2. Pipeline Depth and R&D Strategy

Biogen is scaling its late-stage pipeline, with five Phase III starts in 2025 and multiple data readouts expected through 2026. The pipeline is now more balanced between neuroscience and immunology, reducing historical concentration risk. Notably, the company received FDA fast-track designation for BIB-80, a tau-targeting antisense oligonucleotide (ASO) for Alzheimer’s, based on promising Phase Ib data. The acquisition of ex-U.S. rights to zorubinersen for Dravet syndrome also adds a differentiated rare disease asset.

3. Commercial Innovation and Market Access

Management is adapting commercialization approaches to address unique market challenges. For Lekembe, efforts include IV maintenance dosing, subcutaneous formulations for at-home administration, and direct patient engagement. These changes are designed to reduce physician workload and patient burden, accelerating adoption. In rare diseases, Biogen is leveraging advanced patient-finding tools and expanding field forces, particularly for Skyclarus and Zerzuve, to drive deeper penetration in fragmented patient populations.

4. Operational Discipline and Cost Structure

The Fit for Growth initiative continues to deliver targeted $1 billion in gross and $800 million in net savings, supporting investment in launches and pipeline while offsetting headwinds from legacy erosion. Cost of sales increased due to lower-margin contract manufacturing, but core R&D and SG&A expenses declined 1% year over year, reflecting ongoing prioritization and efficiency gains.

5. Global Footprint and Tariff Resilience

Biogen’s manufacturing and revenue base is unusually globalized, with 55% of product revenue outside the U.S. and substantial U.S.-based production. This structure, along with elevated inventory levels, insulates the company from near-term tariff shocks—even if current exemptions lapse. Management emphasized that 2025 outlook is not at risk from announced or retaliatory tariffs, a differentiator versus peers with more U.S.-centric revenue.

Key Considerations

Biogen’s Q1 marks a visible turning point, but the path to sustainable growth remains complex. Investors should weigh the following:

Key Considerations:

• Launch Product Execution: Commercial uptake of Lekembe, Skyclarus, and Zerzuve will determine whether new revenue can fully offset MS declines.
• Market Access and Reimbursement: European rollout of Lekembe faces incremental hurdles as payers scrutinize cost-effectiveness of first-in-class Alzheimer’s therapies.
• Pipeline Readouts and Regulatory Milestones: Late-stage pipeline progress, especially in immunology and rare disease, is critical for long-term growth and investor confidence.
• Cost Management: Continued delivery on Fit for Growth savings is needed to absorb launch and R&D investment without margin compression.
• Tariff and Supply Chain Strategy: Global manufacturing footprint provides near-term protection, but evolving trade policy remains a watchpoint for future periods.

Risks

Accelerating erosion in the MS franchise, especially with biosimilar Tysabri and generic Tecfidera entries in Europe and a potential U.S. Tysabri biosimilar in Q4, will pressure revenue and margin. Market access delays, reimbursement pushback, and physician adoption hurdles for new launches could slow expected growth. Pipeline execution risk remains, given the complexity of late-stage neurology and immunology assets. Emerging tariff and regulatory changes, while mitigated for 2025, introduce longer-term uncertainty.

Forward Outlook

For Q2 2025, Biogen guided to:

• Continued sequential growth in launch product revenue
• Steeper absolute declines in MS franchise revenue

For full-year 2025, management maintained guidance:

• Mid-single-digit percentage decline in total revenue, as launch product growth is outweighed by MS erosion
• Non-GAAP EPS of $14.50 to $15.50 (reflects Stoke transaction and FX tailwinds)

Management highlighted several factors that shape the outlook:

• Potential U.S. Tysabri biosimilar entry in Q4 and expanding Tecfidera generics in Europe
• Minimal 2025 impact from announced U.S. and China tariffs due to manufacturing structure and inventory

Takeaways

Biogen is in the midst of a portfolio reset, with launch products gaining enough scale to offset, but not yet reverse, legacy headwinds. The company’s ability to deliver on pipeline milestones and accelerate launch uptake will be decisive for future growth.

• Launch Traction: New products are gaining share and visibility, but must continue to scale to outpace MS declines.
• Pipeline Optionality: Five late-stage starts and upcoming readouts provide multiple shots on goal, reducing single-asset risk.
• Watch for Execution: Investor focus should remain on launch ramp rates, reimbursement progress, and pipeline data through 2026.

Conclusion

Biogen’s Q1 underscores a pivotal transition, with new launches and pipeline breadth beginning to reshape the company’s growth profile. The next year will test whether commercial and R&D execution can deliver sustainable returns as legacy franchises fade.

Industry Read-Through

Biogen’s experience highlights the challenge and necessity of portfolio renewal in mature biopharma. The shift to rare diseases, first-in-class neurology, and global diversification is likely to become an industry template as legacy blockbusters face biosimilar erosion. Tariff resilience via U.S.-based manufacturing and ex-U.S. revenue offers a playbook for peers exposed to geopolitical risk. The focus on launch innovation, patient engagement, and payer navigation will be increasingly critical for all companies introducing novel therapies into cost-sensitive markets.

BIIB Healthcare Biotechnology Rare Disease Alzheimer's MS Pipeline Tariffs